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Fanconi Anemia (FA) is an inherited disorder characterized by the variable presence of multiple congenital somatic
abnormalities, bone marrow failure and cancer susceptibility. Medulloblastoma (MB) has been described only in
few cases of FA with biallelic inactivation in the tumor suppressor gene BRCA2/FANCD1 or its associated gene
PALB2/FANCN.
We report the case of a patient affected by Fanconi Anemia with Wilms tumor and unusual presentation of two
medulloblastomas (MB1 and MB2). We identified a new pathogenetic germline BRCA2 mutation: c.2944_2944delA.
Molecular analysis of MBs allowed us to define new features of MB in FA. MBs were found to belong to the Sonic
Hedgehog (SHH) molecular subgroup with some differences between MB1 and MB2. We highlighted that MB in FA
could share molecular aspects and hemispheric localization with sporadic adult SHH-MB. Our report provides new
findings that shed new light on the genetic and molecular pathogenesis of MB in FA patients with implications in
the disease management.
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Fanconi Anemia (FA) is a genetically and phenotypically
heterogeneous disorder, inherited with an autosomal (or
rarely X-linked) recessive pattern, occurring in approxi-
mately 1/100,000 births per year [1]. Main features of FA
are the presence of multiple congenital somatic abnormal-
ities, the gradual onset of bone marrow failure, and a
strong predisposition to cancer. The most common malig-
nancies include acute myeloid leukemia (AML) and mye-
lodysplastic syndrome (MDS), followed by solid tumors,
mostly squamous-cell carcinomas at young age [2–4].
Solid tumors may represent the first manifestation of
FA in individuals without congenital somatic abnormalities* Correspondence: elisabetta.ferretti@uniroma1.it
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creativecommons.org/publicdomain/zero/1.0/or hematological manifestations [5]. These tumors in-
clude squamous cell carcinomas of head and neck,
esophagus, vulva and cervix, liver tumors, and rarely
embryonic tumors.
The hallmark of FA is chromosome fragility and hyper-
sensitivity to DNA interstrand cross-linking agents [6, 7,
1, 8–10]. To date, 17 genes (FANCA, FANCB, FANCC,
FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG/
XRCC9, FANCI, FANCJ/BRIP1, FANCL, FANCM, FANCN/
PALB2/BRIP1, FANCO/RAD51C, FANCP/SLX4, FANCQ/
ERCC4, and FANCS/BRCA1) are known to be involved in
the pathogenesis of FA [1, 8, 9, 11]. The 17 gene products
appear to interact in a common cellular pathway involved
in the regulation of DNA repair. Mutations in eight
FA genes (FANCA, FANCB, FANCC, FANCE, FANCF,
FANCG, FANCL, and FANCM) result in loss of FANCD2
and FANCI monoubiquitination, the central regulatory
event of the FA pathway, while FA proteins downstreamicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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FANCD1/BRCA2) cooperate in DNA repair [5].
Although a clear picture of genotype-phenotype cor-
relation in FA is currently not completely elucidated,
many data suggest that specific complementation groups
play a significant role in both phenotypic expression and
survival [12, 13].
In particular, biallelic mutations in FANCD1/BRCA2
(about 2 % of all FA patients) [14] and FANCN/PALB2
are associated with an extremely high predisposition to
leukemia and solid tumors (e.g. medulloblastoma, Wilms
tumor) at a very early age [15, 16], with a cumulative in-
cidence probability of malignancy of 97 % by the age of
5.2 years in FANCD1/BRCA2 patients [17].
The sequential onset of Wilms Tumor (WT), medullo-
blastoma (MB) and AML has been reported in associ-
ation with mutation in BRCA2 [16–32] (Table 1).Table 1 Previously reported cases of brain tumors associated
Tumor Age (yrs) Sex BRCA2 mutation I BRCA mutation 2 Loc
MB, WT 1.5 F - - NR
MB 3.5 F c.2830A > T c.7964A > G Hem
BT 3 F 7691/insAT 9900/insA NR
PFT 4.9 M c.5946delT 9435 T > A Mid
MAs 2 M c.5946delT 9435 T > A Cer
exon 24
MB 4.5 F c.5946delT c.658_659delGT Cer
MB 2.5 F 5301insA c.7469 T > C NR
MB 3.5 F c.3922G > T c.9196C > T NR
MB 2.3 M c.658_659delGT 8447 T > A Hem
MB, WT (15 mo) 4.3 M c.658_659delGT 8447 T > A Hem
MB 2.9 M - - Hem
GB, WT (3.5 yrs) 9 M c.658_659delGT c.5645C > A Cer
MB, WT (7mo)
ALL-B (10 yrs)
5.7 M c.658_659delGT c.5645C > A Cer
PFT 1 F 1548del4 1548del4 Cer
MB 3.1 F c.5946delT c.9196C > T Cer
PNET or HGG 1.3 M c.5946delT c.658_659delGT Intr
MB 1.7 M c.5946delT c.658_659delGT Hem
MB 2 NR c.3264dup c.IVS19 + 3A > G
(c. 8487 + 3A > G)
NR
MB, WT (8 mo)
AML (24 mo)
2.9 F - - Hem
MB 13 M c.1114A > C c.1114A > C Cer
MB WT (4 yrs) 6 F - - Hem
MB WT(15 mo) 2.9 F c.658_659delGT c.2944delA MB
MB
MB Medulloblastoma, WT Wilms Tumor, BT Brain Tumor, PFT Posterior Fossa Tumor,
– B, PNET Primitive Neuroectodermal Tumor, HGG High Grade Glioma, AML Acute MHere, we report a case of a patient affected by
FA, who sequentially developed WT and unexpected
two distinct MBs, in which we identified a novel patho-
genetic germline BRCA2 mutation and MB molecular
subgroup.
Case presentation
Clinical and neurophatologic features
A 15-month-old female patient born at term, small for ges-
tational age, the second daughter of non-consanguineous
parents was referred to the Bambino Gesù Children
Hospital for macroscopic hematuria due to a large renal
neoplasm in a solitary pelvic cake kidney.
Laboratory tests showed mild renal failure (creatinine
1.37 mg/dl, BUN 46 mg/dl), normocytic anemia (Hb
7.5 g/dl; MCV 77 fl), hyperuricemia (8.4 mg/dl) and in-
creased LDH (1963 UI/dl). Hypertension (both diastolicwith BRCA2 mutations
alization Note Refs
- [22]
ispheric - [19, 30]
- [32]
line Ashkenazi Jewish congenital
anomalies Sibling of the following
[23, 24]
ebellum Ashkenazi Jewish Sibling of the previous [24]
ebellum Mixed Ashkenazi Jewish [24]
Latin American [24]
African American [24]
ispheric Sibling of the following [16]
ispheric Sibling of the previous [16]
ispheric - [20]
ebellum Sibling of the following [27]
ebellum Sibling of the previous [27]
ebellum Consanguinity VACTERL syndrome [25]
ebellum VACTERL syndrome [17]
amedullary Sibling of the following [21]
ispheric Sibling of the previous [21]
- [21]
ispheric Consanguinity [18, 31]
ebellum Desmoplastic histology [26]
ispheric Consanguinity [28]
1: Hemispheric;
2: vermian
MB1, MB2: SHH subtype Current report
MAs Multiple Astrocitomas, GB Glioblastoma, ALL-B Acute Lymphatic Leukemia
yeloid Leukemia, NR not reported, yrs Years, mo Months
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ile) required pharmacological treatment.
Physical examination revealed growth retardation
(both weight and height lower than 3rd percentile), ab-
normal skin pigmentation (both café au lait spots and
hypopigmentation), elfin facies with epicanthus. Echo-
cardiography showed a mitral valve insufficiency. The
patient also had right-convex scoliosis and ribs anomal-
ies. A clinical suspect of FA was formulated and a DEB-
test was performed which showed multiple spontaneous
and DEB-induced chromosomal breaks per cell. Radio-
logic tumor assessment confirmed the presence of a
renal neoplasm (78.1 × 42.2 × 62.8 mm) (Additional file
1: Figure S1a) with bilateral lung metastases (Additional
file 1: Figure S1b).
Neoadjuvant chemotherapy was started, according to
SIOP WT 2001 protocol, obtaining a partial response on
both primary tumor (44 × 33 × 22 mm) (Additional file
1: Figure S1c) and metastatic lesions. Despite dose-
adapted chemotherapy, chosen considering chromo-
somal fragility and according to renal function, the child
experienced a grade-IV hematological toxicity and re-
spiratory failure requiring admission to the intensive
care unit. Afterwards, tumorectomy was performed,
sparing residual renal functioning tissue. Histologic ana-
lysis confirmed a grade-III nephroblastoma, according to
SIOP 2001 classification [33]. Post-surgical chemother-
apy was resumed until completion of the protocol. At
that point, a single residual lung metastasis was present
and therefore resected by thoracotomy with no signifi-
cant complications. Follow up confirmed stable remis-
sion with a mild chronic renal failure.
At the age of 35 months the child was seen with head-
ache and vomiting at the emergency room. A brain com-
puted tomography (CT) scan showed a left cerebellar
hemispheric lesion exerting significant mass effect on
the fourth ventricle. Cranio-spinal magnetic resonance
imaging (MRI) confirmed a localized rounded heteroge-
neously enhancing mass with intralesional cystic compo-
nents and perilesional edema (Fig. 1a-f ). Cytologic
evaluation of the cerebrospinal fluid resulted negative
for neoplastic cells. Gross total resection of the lesion
was performed.
Histology showed a neoplasm with an expanded lobu-
lar architecture, due to the reticulin-free zones rich in
neuropil-like tissue. Such zones contained a population
of small cells with rounded nuclei diagnostic of a desmo-
plastic/nodular medulloblastoma (Fig. 1g-h) without C/
N-myc amplification evaluated by FISH analysis. Due to
previous clinical history and to the persistence of a mild
chronic renal failure, a tailored chemotherapeutic regi-
men with Carboplatin and Vincristine was chosen. Des-
pite the low dose of chemotherapy employed, the patient
presented a significant toxicity after the first course oftreatment including pancytopenia (WHO grade IV), sep-
sis and deterioration of renal function that slowly recov-
ered in 3 months. Considering this relevant toxicity no
further treatment was offered.
At a follow-up MRI, 17 months after the previous sur-
gery for MB, a midline cerebellar mass was detected
(Fig. 2a-d). Complete surgical resection was performed,
and histology showed a large cell neoplasm with vesicu-
lar nuclei, prominent nucleoli and variably abundant eo-
sinophilic cytoplasm consistent with large cell/anaplastic
MB (Fig. 2e-f ). FISH analysis showed N-myc amplified
medulloblastoma cells (Fig. 2g). One month after sur-
gery, a local recurrence with leptomeningeal dissemin-
ation was documented.
Considering the toxicity shown during previous treat-
ments, an evaluation of target molecular expression on
the tumor was performed. Based on the evidence of
expression of P-mTor, a personalized treatment with
rapamycin [34] associated with intrathecal liposomal
cytarabine [35] was started. Despite therapy, patient died
of relapse and disease progression two months after the
diagnosis of the second MB at 55 months of age.
Genetics
Based on published data, the onset of MB after a WT in
this FA patient raised the suspicion of a biallelic muta-
tion in FANCD1/BRCA2. To confirm this hypothesis, we
performed a genetic analysis of FANC1/BRCA2 on pa-
tient’s DNA extracted from both from peripheral blood
and MB1 cells, which revealed the presence of com-
pound heterozygosis for BRCA2 frameshift mutations.
Gene-specific BRCA2 analysis, including sequencing of
all translated exons and adjacent intronic regions of the
BRCA2 gene, was performed on the DNA samples. Both
the truncating and novel genetic variants were con-
firmed by sequencing two different blood samples on
both DNA strands. Sequencing was performed using an
ABI PRISM DyeDeoxy Terminator Cycle Sequencing Kit
and an ABI 3100 Genetic Analyzer (Thermo Fisher Sci-
entific, Waltham, MA USA). Reference sequence for
BRCA2: Genebank, NM_000059.1. By this mean, we re-
vealed a compound heterozigosity for two distinct fram-
shift mutations: the already described c.658_659delGT
(p.Val220Ilefs) mutation on BRCA2 exon 8, and a previ-
ously unknown c.2944_2944delA (p.Ile982Tyrfs) muta-
tion on BRCA2 exon 11 (Fig. 3)a and b, both of which
are predicted to lead to truncated BRCA2 proteins. Gen-
etic testing of the parents confirmed they both were het-
erozygous carriers; in particular, the father carried the
c.658_659delGT mutation, while the mother carried the
c.2944_2944delA mutation (Fig. 3c and d). Further ana-
lysis of the pedigree suggested the segregation of the
mutations in the paternal grandfather and in the mater-
nal grandmother, not affected by cancer. The original
Fig. 1 Imaging and Histopatological features of MB1. Axial CT (a) and axial conventional MR (b T2w, c FLAIR T2w, d T1w) images demonstrate a
heterogeneous posterior fossa tumor in the left cerebellar hemisphere with mild surrounding edema (arrowheads) and significant mass effect on
the fourth ventricle. The lesion shows a hypointense rim (white arrows) and a cystic component on its medial side (*). Apparent diffusion
coefficient map (e) reveals restricted diffusion in solid tissue (black arrows). On the perfusion sequences (f) by arterial spin labeling, the tumor was
depicted as a low perfusion area. (g) Neoplasm is composed of densely cells with round to oval shaped hyperchromatic nuclei with scanty
cytoplasm. (h) Neoplastic cells are arranged in nodule surrounded by a reticular fiber network (Gomori stain)
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nal grandfather affected with pancreatic cancer, which
belongs to the spectrum of FA/BRCA-associated tumors
(Fig. 3e). Overall, the genealogical chart was character-
ized by a low occurrence of tumors both in paternal and
maternal families and in particular by the absence of
breast and ovarian cancer cases (Fig. 3e). Analysis of the
MB1 tumor tissue from the affected child revealed het-
erozygosis for both alleles, thus suggesting both of them
are selected for in tumor development.
MBs molecular features
We performed gene expression analysis of both hemi-
spheric MB1 and vermian MB2 by real-time quantitative
PCR (RT-QPCR). We used TaqMan Low Density Array
custom designed with TaqMan assays (Life Technologies -
Thermo Fisher Scientific, Waltham, MA USA) for genes of
interest for medulloblastoma subgrouping, according to
Northcott 2012 [36, 37], while we used single TaqManassay (Life Technologies - Thermo Fisher Scientific,
Waltham, MA USA) for all other shown mRNA analyses
[38]. Gene expression analysis on samples was performed
using a ViiA7 sequence detection system according to the
manufacturer’s instructions. RNA of normal human cerebel-
lum (7 adult samples from 25- to 70-year-old subjects were
purchased from Biocat (Heidelberg, Germany), Ambion
(Life Technologies - Thermo Fisher Scientific, Waltham,
MA USA) and BD Biosciences (San Jose, CA) [38].
Unsupervised clustering and heatmaps were generated
using the analyzed transcript levels expressed as Delta
Ct values as input. We used Spotfire software (TIBCO
Software, Inc. CA, USA) to cluster the samples and to
generate the heatmaps, as previously described [39, 40].
The results showed a clear Sonic-hedgehog (SHH) mo-
lecular subgroup for MB1 (Fig. 4a and Additional file 2:
Figure S2) while MB2, though characterized as SHH-
MB, was found to express genes associated with group 3
and 4 MBs (such as GABRA5, KHDRBS2 - Fig. 4b).
Fig. 2 Imaging and Histopatological features of MB2. MRI. Axial T2-weighted image (a) and sagittal T1-weighted image (b) show a nodular mass
originating from the vermis and bulging into the fourth ventricle. Apparent diffusion coefficient (ADC) map (c) shows lack of diffusion restriction.
Perfusion weighted imaging (d) reveals hyperperfusion within the lesion. (e) Tumor is characterized by pleomorphic cells with large nuclei,
prominent nucleoli and moderate eosinophilic cytoplasm. (f) Large cells show immunoreactivity for synaptophysin. (g) N-Myc oncogene amplification
(green spots) detected in neoplastic nuclei (blue) and centromere 8 signals (red spots) using CEP8/BAC as FISH probes. Red arrow: N-Myc amplified cell.
White arrow: N-Myc dyploid cell
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between the two MBs. Gli1, the transcription factor of
the Hedgehog (Hh) pathway, was highly expressed in
MB1, together with all its downstream targets (PTCH1,
PTCH2, IGF2, HHIP, SFRP1, CCND1) (Fig. 5a and b);
while MB2 showed lower levels of Gli1 and its target
genes (Fig. 5b). Conversely, Gli2 was highly expressed in
MB2 (Fig. 5a), while CCND2 was expressed at very low
levels (Fig. 5c). Of note, N-myc amplification was only
found in MB2 (Fig. 2g and Fig. 5d). Moreover, differ-
ences were found in the expression of stem cell/differen-
tiation genes: MB2 was characterized by low expression
of lineage differentiation genes (ZIC1, BMP2, GFAP,
GABRA6) (Fig. 5e) accompanied by expression of stem-
ness genes, such as PROM1 and C-MYC (Fig. 5d), when
compared to MB1.
Genes associated with chromatin modifications, such
as histone methylases/demethylases and polycomb
(EZH2, KDM6B, KDM6A, BMI1) and the homeobox
transcription factor OTX2 [41], were also evaluated. In-
deed, large cell/anaplastic MB2 showed higher levels of
EZH2, OTX2 and KDM6B and lower levels of KDM6A
and BMI1 (Fig. 5f ).
Finally, hemispheric localization of MB is rare in in-
fancy, while is common in adulthood. Moreover, despite
the common activation of Hh signaling, infant, child-
hood and adult SHH MBs have been demonstrated to beclinically, transcriptionally, genetically and prognostically
distinct [42, 43].
Thus, we investigated the gene expression pattern of
MB1 and MB2, compared to adult, childhood and infant
sporadic SHH-MBs. We analyzed a panel of genes by
RT-QPCR among the top 250 reported to be differen-
tially expressed in the three classes of ages [43]. Our
data are consistent with those reported by Kool 2014
that identified two major clusters mainly separating in-
fant from childhood and adult SHH MBs. Moreover, our
analysis showed that hemispheric MB1 (diagnosed under
3 years of age) clustered with adult/childhood MBs
(Fig. 6), while vermian MB2 (diagnosed after 3 years of
age) clustered with infant SHH MBs (Fig. 6).
Discussion
This analysis allowed us to better define features of MBs
in FA. We identified a new pathogenetic germline
BRCA2 mutation in FA; both MBs belonged to SHH
molecular subgroup with a more “aggressive” phenotype
in MB2, and, finally, we documented that MB1 shared
similarities with sporadic adult SHH-MB, such as hemi-
spheric localization and gene expression pattern.
In our patient, the first manifestation that led to the
diagnosis of FA was the onset of WT.
WT and MB in FA have been reported in few cases
and are associated with mutations of FANCD1/BRCA2
Fig. 3 (See legend on next page.)
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Fig. 3 Genetic Analyses. Direct sequencing data relative to the indicated region of BRCA2 gene demonstrating the biallelic mutations
c.2944_2944delA exon 11 and c.658_659delGT exon 8 in patient’s blood (a) and tumor (b), present in mother’s blood (c) and father’s blood (d)
respectively. MUT: mutated case, WT: wild type case. (e) Family pedigree: closed symbol: affected with cancer, open symbol: unaffected with
cancer. The type of cancer and age at presentation are given under the symbol. Arrow: proband, blue plus sign: BRCA2 c.658_659delGT exon 8
mutation, red plus sign: BRCA2 c.2944_2944delA exon11 mutation. Pro: prostate cancer, Pan: pancreatic cancer, Ov: ovarian cancer, CNS: central
nervous system tumor, Gas: Gastric cancer, WT: Wilms Tumor, MB: Medulloblastoma
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44]. Based on this evidence, we investigated BRCA2 muta-
tional status and confirmed the presence of biallelic trun-
cating mutations in the FA patient. The c.658_659delGT
mutation occurring on BRCA2 exon 8 had been previ-
ously reported in hereditary breast/ovarian cancer cohorts
(see in example [45]) and is one of the most frequently oc-
curring in FANCD1/BRCA2 mutated FA cases [29]. TheFig. 4 Molecular characterization of MB1 and MB2. Histograms showing m
normal cerebella (average of n = 7) as control (CTR). Genes are grouped an
which they identify (SHH, WNT, GROUP 3, GROUP 4). The values of Relativesecond truncating mutation, the previously undescribed
c.2944_2944delA (p.Ile982Tyrfs), occurs on BRCA2 exon
11. The segregation analysis among the available relatives
allowed us to assign the two mutations as of paternal and
maternal origin, respectively. The absence of breast and
ovarian cancer cases in the pedigree could appear surpris-
ing, at first. However, both paternal and maternal sides of
the tree were characterized by a relatively small number ofRNA levels of the indicated genes in MB1 (a) and MB2 (b) compared to
d depicted in different colors, depending on the molecular subgroups,
Quantification are expressed in log10 scale
Fig. 5 Gene expression analysis of MB1 and MB2. Histograms show mRNA levels of the indicated genes in MB1 and MB2 compared to normal
cerebella (average of n = 7) as control (CTR). In detail (a) GLI family members; (b) Sonic Hedgehog pathway (Hh) molecules and direct targets. (c)
Cyclins. (d) Myc genes and Stemness molecules; (e) Differentiation molecules; (f) Epigenetic modifiers. The values of Relative Quantification are
expressed in linear scale for panels (a), (c), (d), (e) and (f) and log scale for panel (b)
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lele was inherited by the patient via two male carriers
(father and grandfather) and the only female member on
this line (affected by gastric cancer) was not available for
segregation analysis. The c.2944_2944delA allele, possibly
coming from the mother’s maternal grandfather affected
with pancreatic cancer, reached the patients via a 64 years
old grandmother and a 36 years old mother, a female car-
rier of rather young age compared to 43 and 54 years, the
mean ages of breast and ovarian cancer diagnosis, respect-
ively, recently reported in a very large cohort analysis [46].
The preponderance of male relatives in this side of the
tree further hindered any possible speculation on the role
of the c.2944_2944delA on breast and ovarian cancer
predisposition.Complete BRCA1 or BRCA2 loss is lethal in mice [47].
This is likely to be the case also in humans, since no
biallelic BRCA2 mutations occurring 5′ to exon 7 have
been reported in FA patients so far, while monoallelic
truncating mutations from exon 2 to exon 7 have been fre-
quently associated with breast/ovarian cancer susceptibility.
In three out of four FA patients, the c.658_659delGT muta-
tion occurred in association with a truncating mutations of
exon 11 [29]. This is also the case for the patient described
here, in which the c.658_659delGT mutation is associated
with a truncating mutation of BRCA2 exon 11, the previ-
ously undescribed c.2944_2944delA (p.Ile982Tyrfs) muta-
tion. Overall, these data suggest that BRCA2 truncation
downstream of exon 7/8 is probably hypomorphic, but still
compatible with life especially in association with exon 11
Fig. 6 Heatmap and results of an unsupervised hierarchical clustering
derived from the -DCt values of the analyzed genes in MB1 and MB2
(Case FA) and in adult (n = 4, A1, A2, A3, A4), childhood (n = 4, Ch1,
Ch2, Ch3, Ch4) and infant (n = 4, I1, I2, I3, I4) SHH-MBs. Nodal numbers
indicate bootstrap values obtained by resampling the data
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Meyer, homozygous or compound heterozygous exon 11
mutations have not been reported in FA patients despite
the relatively high frequency of these alleles. Together with
the report of the recurrent miscarriages in Jewish BRCA2
mutation carriers [29], this suggests that biallelic exon 11
BRCA2 mutation may also be incompatible with life. More
definitive answers on this topic may come from directly ad-
dressing this issue in specifically modeled mice.
MB in FA patients reported in the literature typically
show cerebellar hemispheric localization and desmoplas-
tic histology, as we observed in MB1 (Table 1). Cerebel-
lar hemispheric MBs are frequently desmoplastic and
belong to the SHH subgroup, especially in adults [48].
Hemispheric location is consistent with the results from
MB mouse models that have shown SHH-MB origin
from committed granule neuron precursors (GNPs) of
the cerebellum. Teo et al., reported hemispheric involve-
ment in 9 of 17 (53 %) SHH-MBs, regardless of age at
diagnosis [49]. In Perreault study [48], SHH lesions
rarely invaded the brain stem, consistent with a prior
study that reported brain stem infiltration by WNT, but
not by SHH tumors [50].
Gene expression analysis of our MBs allowed us to
clearly define that both MB1 and MB2 belonged to
SHH subgroup.
Biological explanation of the association between FA
and SHH-MB has been analyzed in different papers.Frappart et al. first showed that BRCA2 loss affects
neurogenesis and promotes MB growth, using a mouse
model harboring neural tissue-restricted BRCA2 inacti-
vation [51]. They also identified PTCH1 (a gatekeeper
gene often inactivated in MB) as a critical target in all
DNA repair-deficient MB.
Indeed, defective DNA repair mechanisms render FA
cells prone to DNA interstrand crosslinks (ICLs) caused
by both endogenous (e.g. reactive aldehydes) and ex-
ogenous agents (e.g. alkylating chemotherapeutic drugs)
[1, 5, 52, 53]. The FA pathway is activated by an ICL
during the S phase: the replication fork is stalled and FA
core complex is recruited (FANCA, B, C, E, F, G, L, and
M). Then, FANCL ubiquitinates the FANCD2-FANCI
(ID2) complex, essential for nucleolytic incisions and
translesion synthesis repair events. The complex then
“unhooks” ICL, allowing homologous recombination re-
pair by FANCD1/BRCA2, FANCJ/BRIP1, FANCN/
PALB2, FANCO/RAD51C, and FANCS/BRCA1 (Fig. 7).
Huang et al. reported that conditional knockdown
BCCIP (BRCA2-interacting protein with a role in hom-
ologous recombination and chromosome stability) in
concomitance with p53 deletion caused rapid develop-
ment of MB in the external granular layer, triggered by
SHH pathway activation [54] via the inactivation of the
Ptch1 gatekeeper tumor suppressor [54]. As reported
above, biallelic PALB2/FANCN mutation carriers show a
cancer spectrum comparable to those with biallelic
BRCA2/FANCD1, characterized by early onset AML and
embryonic tumors, including MB and WT [44]. This ob-
servation strengthens the role of BRCA2 in medulloblas-
tomagenesis, since FANCN (also known as ‘partner and
localizer of BRCA2′, PALB2) is well known to co-
localize with BRCA2 in the nucleus [55]. Interestingly,
BRIP1/FANCJ maps on 17q chromosome, a region fre-
quently deleted in MBs [56]. Thus, deleterious mutations
in one of the members of the homologous recombin-
ation machinery could lead to MB onset (Fig. 7). This
feature may provide the rationale for new therapeutic
approaches for MB, as also suggested by Bayrakli et al.
[26]. Platinum compounds or similar drugs, inducing
growth arrest by ICL-stalled- DNA replication fork,
could be combined with agents which take advantage of
the incapacity of HR-deficient neoplastic cells to face up
this stall (e.g. enzyme poly-ADP-ribose polymerase I)
[26]. Indeed, PARP- inhibition has already been shown
to sensitize childhood glioma, medulloblastoma and
ependymoma to radiation [57].
It has been reported that MBs do not change subgroup
at the time of recurrence and that SHH tumors more
frequently have tumor bed recurrence than metastatic
dissemination [58–60]. Even though we cannot com-
pletely rule out that the second MB was not a distant re-
lapse from the first one, in our patient, the occurrence
Fig. 7 Fanconi Anemia Pathway. Endogenous and exogenous agent cause interstrand crosslink lesions (ICL). When an ICL occurs, the replication
fork is stalled and the FA pathway is activated with the recruitment of the FA core complex (FANCA, B, C, E, F, G, L, and M). FANCL ubiqiuitinates
the FANCD2-FANCI (ID2) complex that guides the nucleolytic incisions and translesion synthesis repair events by “unhooking” the ICL. This allows
the homologous recombination repair through FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, and FANCS/BRCA1. Yellow stars
highlight FA/HR repair molecules that have been found genetically inactivated in FA patients with medulloblastoma. BCCIP is a BRCA2 interacting
protein which is able to induce medulloblastoma growth when genetically loss in concomitance with p53 deletion (See text). Readapted
from [52]
Miele et al. Biomarker Research  (2015) 3:13 Page 10 of 13of MB2 with a different localization, a more aggressive
histology, and distinct gene expression patterns could be
suggestive for a second tumor. We hypothesize thatHedgehog signaling activation could have been triggered
in two distinct cells of origin. Indeed, MBs have long
been known to arise in GNPs in the external granule
Miele et al. Biomarker Research  (2015) 3:13 Page 11 of 13layer (EGL) and, more recently, GNPs derived from
cochlear nuclei of the brainstem [61]. SHH-dependent
MBs may also arise from neural stem cells (NSCs) of the
subventricular zone (SVZ). The different tumor location
and expression levels of stemness/differentiation genes
sustain this assumption. MB2 was characterized by
higher levels of EZH2, which trimethylates histone 3 ly-
sine 27 (H3K27me3), concurrently with down regulation
of the lysine demethylase 6A (KDM6A), which removes
the same repressive mark on chromatin (Fig. 5e). Both
these events converge on shutting off oncosuppressor/
differentiation genes and contribute to the maintenance
of a more “cancer stem-like” phenotype [37, 62].
It has been reported that pediatric and adult SHH-MBs
are clinically and molecularly distinct [42, 43]. In a data
analysis based on Whole Genome Sequencing Kool et al.
reported that the molecular differences among infant,
childhood and adult SHH-MBs reside not only at the tran-
scriptional level, but also in DNA methylation [43].
In our report, we found that the hemispheric, desmo-
plastic, myc-not amplified SHH MB1 was more similar
to other adult/childhood SHH-MBs, while the vermian,
large cell/anaplastic, N-myc amplified MB2 was more
similar to infant SHH-MB. The hypothesis of different
cells of origin stands also for such differences between
adults and infants SHH-MBs.
Lastly, the suspect of SHH-MB in FA could direct the
therapy toward a tailored approach, based on the use of
PARP inhibitors or/and SHH inhibitors. However, giving
the specific genetic background (BRCA2), it is highly un-
likely that these tumors have PTCH1 or SMO mutations
making them sensitive to the ‘upstream’ Hedgehog inhibi-
tors targeting SMO. It is more likely that they have acti-
vated the SHH pathway more downstream at the level of
MYCN and probably also GLI2 amplification (as probably
in our MB2). Indeed, as Kool et al. have shown in their re-
cent paper, these tumors are resistant to these ‘upstream’
Hedgehog inhibitors [43]. Inhibitors that target downstream
components of the Hh pathway are under pre-clinical
evaluation [63] (e.g. Gant61 [64], Glabrescione B [65]).
Conclusion
In conclusion, we report a novel BRCA2 mutation in a
FA patient with diagnosis of two distinct MBs. Molecu-
lar features of MB in our FANCD1/BRCA2 patient high-
light that MB in FA patients belongs to SHH subgroup.
Two points are worthy of discussion, due to potential
clinical implications. First, it is important to suspect a
diagnosis of FA in patients whose first manifestations
are embryonic tumors with a sequence WT-MB.
Second, the identification of SHH subtype MB in FA
patients with FANCD1/BRCA2 mutations may play a crit-
ical role for targeted therapeutic interventions. Indeed, in
patients characterized by a peculiar difficulty in cancertherapeutic management, due to the underlying chromo-
somal instability, a benefit could be provided by target
therapy or new combined therapies.
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